Open Access

REVIEW

Future perspectives on cell therapy for autism spectrum disorder

MAKOTO NABETANI^1,*, TAKEO MUKAI²

1 Department of Pediatrics, Yodogawa Christian Hospital, Osaka, 533-0024, Japan
2 Department of Cell Processing and Transfusion, The Institute of Medical Science, The University of Tokyo, Tokyo, 108-8639, Japan

* Corresponding Author: MAKOTO NABETANI. Email:

BIOCELL 2022, 46(4), 873-879. https://doi.org/10.32604/biocell.2022.018218

Received 02 July 2021; Accepted 27 August 2021; Issue published 15 December 2021

Abstract

Autism spectrum disorder (ASD) is a complex neurodevelopmental condition characterized by impairments in social communication, abnormal to absent verbal communication, the presence of repetitive stereotypic verbal and non-verbal behaviors and restricted interests, with onset early in life. We showed cognitive and behavioral characteristics of ASD by impairment of communication, cognition, perception, motor skills, executive function, theory of mind and emotion control. Recently, pathogenesis of immune pathology in the brains of individuals with ASD has been focused. New therapeutic approaches in the viewpoints of immune modulation and microglial function are logical for novel treatments for individuals with ASD. Cell therapies such as umbilical cord blood cells and mesenchymal stromal cells for ASD will be a challenging and encouraging field in the future clinical study with progress of biotechnological science.

---

Keywords

---